Plain-English translation of NCT06799065 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is the first study in humans testing a medication called , an oral pill designed to fight advanced solid tumors by targeting a specific protein involved in cancer cell division. The medication works by disrupting how cancer cells organize their chromosomes during cell division, potentially stopping tumor growth. Researchers want to find the right dose and learn whether this treatment is safe and effective for patients with cancers including ovarian and breast cancer.
Many patients with advanced ovarian and breast cancers stop responding to standard treatments and have limited options. This medication targets a new mechanism in cancer cells that laboratory studies suggest could be effective, offering hope for patients whose tumors have become resistant to current therapies.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth at doses determined by the study team, starting with lower doses in the first phase and potentially increasing based on safety data. The trial has two stages: first, researchers will enroll small groups at different doses to find the safest and most effective dose, then expand to test that dose in more patients with specific tumor types. You would have regular clinic visits for blood tests, physical exams, and imaging scans to monitor how you're responding and watch for any side effects.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States